Abstract

Jab1 has gained tremendous attention as a potent target in cancer therapeutics. Jab1 has been associated with the progression of numerous carcinomas by exhibiting several negative roles, such as degradation of tumor suppressor genes. We have mainly focused our research on elucidating inhibitory phytocompound (flavonoid) that could inhibit the Jab1 expression in cervical cancer, one of the most globally recognized gynecologic malignancies. Moreover, this study would provide a better targeted therapeutic approach for the management of cervical cancer. Although numerous flavonoids have presented potent cytotoxic and antitumor efficacy against HeLa cells, the inhibitory potential of some flavonoids against Jab1 has not been explored yet. Therefore, the current research aims to explore the inhibitory potential of flavonoids against Jab1 in cervical cancer. A total of eleven potent phytocompounds have been selected for screening potent phytocompound that could inhibit HeLa cancer cell growth via Jab1 downregulation. In silico findings demonstrated baicalein as the best Jab1 inhibitory phytocompound. Additionally, MTT assay and RT-PCR analysis have also strongly validated its inhibitory potential against Jab1 in cervical cancer. However, the further detailed analysis needed to be done to elucidate a novel mechanism that could help identify a novel and potent therapeutic phytocompound for drug development against cervical cancer.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.